Search Results - "MILKOVICH, Gary"

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis by Botton, Stéphane, Brandwein, Joseph M., Wei, Andrew H., Pigneux, Arnaud, Quesnel, Bruno, Thomas, Xavier, Legrand, Ollivier, Recher, Christian, Chantepie, Sylvain, Hunault‐Berger, Mathilde, Boissel, Nicolas, Nehme, Salem A., Frattini, Mark G., Tosolini, Alessandra, Marion‐Gallois, Roland, Wang, Jixian J., Cameron, Chris, Siddiqui, Muhaimen, Hutton, Brian, Milkovich, Gary, Stein, Eytan M.

“…Background The present study evaluated the relative survival benefits associated with enasidenib and current standard of care (SoC) therapies for patients with…”
Get full text

Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma by Avigan, Zachary M., Arinsburg, Suzanne, Pan, Darren, Mark, Tomer, Fausel, Christopher, Bubalo, Joseph, Milkovich, Gary, Moshier, Erin, Fu, Weijia, Chari, Ajai, Richter, Joshua

“…Autologous stem cell transplantation is a standard treatment strategy for patients with multiple myeloma that requires effective mobilization and apheresis of…”
Get full text

Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma by Avigan, Zachary M, Arinsburg, Suzanne, Pan, Darren, Mark, Tomer, Fausel, Christopher, Bubalo, Joseph, Milkovich, Gary, Moshier, Erin, Fu, Weijia, Chari, Ajai, Richter, Joshua

Get full text

Future pharmacoeconomic criteria for the treatment of infections by Milkovich, Gary

“…Abstract Skin and soft tissue infections (SSTI) are a common cause of antibiotic prescriptions and loss of time from school and work. Economic pressures on the…”
Get full text

A Retrospective Record Review of Mobilization Strategies with and without Plerixafor for Autologous Stem Cell Transplant in Patients with Multiple Myeloma by Mark, Tomer M, Bubalo, Joseph S, Milkovich, Gary, Barnes, Yvonne J, Drea, Edward, Fausel, Chris

“…Background: Autologous hematopoietic stem cell transplantation (ASCT) is the current standard of care in patients with multiple myeloma (MM) to support…”
Get full text

Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis by Mohty, Mohamad, Azar, Nabih, Chabannon, Christian, Le Gouill, Steven, Karlin, Lionel, Farina, Lucia, Milkovich, Gary, Ostermann, Helmut, Glaß, Bertram, Noppeney, Richard, Kron, Florian, Kron, Anna, Hübel, Kai

“…High-dose chemotherapy alongside peripheral blood stem cell (PBSC) infusion has become the standard of care in different hematologic malignancies. The goal of…”
Get full text

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs by Hübel, Kai, Ostermann, H., Glaß, Bertram, Noppeney, Richard, Kron, Florian, Kron, Anna, Milkovich, Gary, Mohty, Mohamad

“…Mobilization and collection of peripheral blood stem cells is part of the standard treatment procedure for non-Hodgkin’s lymphoma patients eligible for…”
Get full text

POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study by Gordan, Lucio, Tan, Carlyn Rose, Vescio, Robert, Ye, Jing Christine, Schinke, Carolina, Medhekar, Rohan, Fu, Alex Z., Lafeuille, Marie-Hélène, Thompson-Leduc, Philippe, Khare, Vipin, Reitan, John, Milkovich, Gary, Kaila, Shuchita, Davies, Faith, Usmani, Saad Z.

Get full text

P-115 Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study by Gordan, Lucio, Tan, Carlyn Rose, Vescio, Robert, Ye, Jing Christine, Schinke, Carolina, Medhekar, Rohan, Fu, Alex, Lafeuille, Marie-Helene, Thompson-Leduc, Philippe, Khare, Vipin, Reitan, John, Milkovich, Gary, Kaila, Shuchita, Davies, Faith, Usmani, Saad

Get full text

MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study by Gordan, Lucio, Tan, Carlyn Rose, Vescio, Robert, Ye, Jing Christine, Schinke, Carolina, Medhekar, Rohan, Fu, Alex Z., Lafeuille, Marie-Hélène, Thompson-Leduc, Philippe, Khare, Vipin, Reitan, John, Milkovich, Gary, Kaila, Shuchita, Davies, Faith, Usmani, Saad Z.

“…Daratumumab with lenalidomide and dexamethasone (DRd) or bortezomib with lenalidomide and dexamethasone (VRd) are the only guideline recommended preferred…”
Get full text

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls by Paschka, Peter, Dombret, Hervé, Thomas, Xavier, Recher, Christian, Chantepie, Sylvain, Montesinos Fernandez, Pau, Acuña-Cruz, Evelyn, Vyas, Paresh, Kreuzer, Karl-Anton, Heuser, Michael, Metzeler, Klaus H., Dennis, Michael, Quesnel, Bruno, Hunault-Berger, Mathilde, Mohty, Mohamad, Pigneux, Arnaud, De Botton, Stephane, Weber, Daniela, Döhner, Konstanze, Milkovich, Gary, Reitan, John, MacDonald, Sarah C, Casso, Deborah, Storm, Michael, Liu, Hua, Kapsalis, Stephanie M., Attar, Eyal C., Winkler, Thomas, Döhner, Hartmut

“…Background: A European Marketing Authorization Application for ivosidenib (IVO) is currently under review for the indication of mutant isocitrate dehydrogenase…”
Get full text

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study by Gordan, Lucio Navarro, Tan, Carlyn Rose, Vescio, Robert, Ye, Jing Christine, Schinke, Carolina, Medhekar, Rohan, Fu, Alex Z, Lafeuille, Marie-Hélène, Thompson-Leduc, Philippe, Khare, Vipin, Reitan, John, Milkovich, Gary, Kaila, Shuchita, Davies, Faith, Usmani, Saad Z

“…Daratumumab, lenalidomide and dexamethasone (DRd) and bortezomib, lenalidomide and dexamethasone (VRd) are preferred regimens for transplant ineligible (TIE)…”
Get full text

Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective by Cremaschi, Liana, von Versen, Regina, Benzing, Thomas, Wiesener, Michael, Zink, Nikolai, Milkovich, Gary, Paivanas, Thomas, Gallagher, Meghan, Thaiss, Friedrich

“…A health economic analysis was undertaken based on the 1-year database from a randomized study of rabbit anti-human thymocyte immunoglobulin (rATG) versus…”
Get more information

Intravenous-to-oral transition therapy in community-acquired pneumonia : The INOVA Health System experience: Optimizing antiinfective transition therapy in community-acquired pneumonia by MILKOVICH, Gary

Get full text

A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria by Slama, Thomas G, Amin, Alpesh, Brunton, Stephen A, File, Jr, Thomas M, Milkovich, Gary, Rodvold, Keith A, Sahm, Daniel F, Varon, Joseph, Weiland, Jr, David

“…In response to the overuse and misuse of antibiotics, leading to increasing bacterial resistance and decreasing development of new antibiotics, the Council for…”
Get more information

Adverse Events Associated with Commonly Used Cancer Regimens by MILKOVICH, Gary

Get full text

Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention by Milkovich, G, Gibson, G

“…The economics of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention (PCI) are discussed. More than 1 million…”
Get full text

Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention: Clinical and economic implications of bleeding after percutaneous coronary intervention by MILKOVICH, Gary, GIBSON, Gene

Get full text

The role of the hospital pharmacist in cost control and antibiotic policy by Milkovich, Gary

“…The pharmacist provides a vital role in the management of antibiotic policy. Consumers and payers demand quality care at a significantly reduced price. It is…”
Get full text

Intravenous-to-Oral Transition Therapy in Community-Acquired Pneumonia: The INOVA Health System Experience by Milkovich, Gary

“…Economic pressures on the delivery of health care have necessitated a focus on reducing costs and resource utilization while maintaining or improving the…”
Get full text